New

Cyramza 100 mg

₹ 0.00~~₹ 0.00~~

Brand Name: Cyramza
Generic Name: Ramucirumab

Cyramza 100 mg Injection contains ramucirumab, a recombinant human IgG1 monoclonal antibody used as a targeted cancer therapy. It works by interfering with vascular endothelial growth factor receptor 2 (VEGFR-2), a receptor involved in the formation of new blood vessels that can support tumor growth.

Description

Cyramza 100 mg Injection

Cyramza 100 mg Injection contains Ramucirumab, a targeted anticancer medicine that belongs to the vascular endothelial growth factor (VEGF) inhibitor group. Doctors use Ramucirumab to treat certain advanced or metastatic cancers, including gastric or gastroesophageal junction cancer, non-small cell lung cancer, colorectal cancer, and selected cases of hepatocellular carcinoma.

Cyramza 100 mg Injection is supplied as a 100 mg/10 mL solution and is administered directly into a vein as an intravenous infusion by a qualified healthcare professional. Your doctor decides the appropriate dose and treatment schedule based on the type of cancer, previous treatment, overall health, and response to therapy.

Uses of Cyramza 100 mg Injection

Cyramza 100 mg Injection may be prescribed for specific advanced or metastatic cancers.

Stomach Cancer

Ramucirumab can be used alone or with paclitaxel to treat adults with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma that has progressed after previous fluoropyrimidine- or platinum-containing chemotherapy.

Non-Small Cell Lung Cancer

Ramucirumab can be used with docetaxel for certain adults with metastatic non-small cell lung cancer whose disease has progressed after platinum-based chemotherapy. In specific EGFR-mutated cases, doctors may use Cyramza with erlotinib as first-line treatment.

Colorectal Cancer

Doctors may combine Ramucirumab with FOLFIRI to treat adults with metastatic colorectal cancer that has progressed after previous treatment with bevacizumab, oxaliplatin, and a fluoropyrimidine.

Liver Cancer

Ramucirumab may be used alone for adults with hepatocellular carcinoma who have an alpha-fetoprotein (AFP) level of at least 400 ng/mL and previously received sorafenib.

Therapeutic Effects of Ramucirumab

Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2). VEGFR-2 plays an important role in the formation of new blood vessels that can supply growing tumors.

By binding to VEGFR-2, Ramucirumab blocks VEGF-related signaling and can reduce the formation of new blood vessels around the tumor. This can slow the growth and progression of certain cancers.

Interaction with Other Drugs

Cyramza may interact with certain medicines or increase specific treatment-related risks. Always tell your oncologist about every medicine, supplement, or herbal product you use.

Blood-Thinning Medicines

Ramucirumab can increase the risk of bleeding. Tell your doctor if you take anticoagulants, antiplatelet medicines, or other medicines that affect blood clotting.

Chemotherapy Medicines

Cyramza is commonly used in combination with medicines such as paclitaxel, docetaxel, FOLFIRI, or erlotinib for specific cancers. Your oncologist will select and monitor the combination according to your treatment plan.

Other Medicines

Tell your healthcare team about all prescription medicines, over-the-counter medicines, vitamins, and supplements before starting Ramucirumab.

More Information

Cyramza 100 mg Injection contains Ramucirumab 100 mg in 10 mL. It is supplied as a solution for intravenous infusion and must be administered by a healthcare professional.

Storage

Store Cyramza in a refrigerator at 2°C to 8°C. Keep the vial in its original carton to protect it from light. Do not freeze or shake the vial.

Prescription Medicine

Cyramza is a prescription anticancer medicine. Only an oncologist or qualified healthcare professional should determine whether Ramucirumab is appropriate for your condition.

How to Administer Cyramza 100 mg Injection

Cyramza 100 mg Injection is given through an intravenous infusion. Do not self-administer this medicine. A healthcare professional prepares and administers the infusion while monitoring you for possible infusion-related reactions.

Dosage

The Ramucirumab dose depends on the type of cancer and the treatment combination being used. For some indications, doctors use weight-based dosing such as 8 mg/kg, while other indications may require 10 mg/kg. Your oncologist will calculate the appropriate dose for you.

Infusion

Healthcare professionals may give medicines before the Cyramza infusion to reduce the risk of infusion-related reactions. Your medical team will monitor your blood pressure and watch for symptoms such as chills, fever, rash, breathing difficulty, or chest discomfort during or after the infusion.

Dose Changes

Your doctor may delay, reduce, or discontinue Ramucirumab treatment if you develop certain serious side effects such as severe hypertension, significant bleeding, proteinuria, impaired wound healing, or other treatment-related complications.

Safety Advice

Breastfeeding

Do not breastfeed while receiving Cyramza unless your doctor specifically advises you otherwise. The potential effects of Ramucirumab on a breastfed infant are not fully established, and the treatment may pose a potential risk. Discuss breastfeeding with your oncologist before starting treatment.

Alcohol

The safety of consuming alcohol with Cyramza has not been clearly established. Discuss alcohol use with your oncologist, particularly if you are receiving chemotherapy at the same time.

Liver

Tell your doctor if you have liver disease, cirrhosis, or other liver problems. Ramucirumab can require careful monitoring in patients with underlying liver disease, particularly those being treated for hepatocellular carcinoma.

Kidney

Tell your doctor if you have kidney disease or protein in your urine. Ramucirumab can cause proteinuria, and your doctor may regularly check your urine during treatment.

Lungs

Inform your doctor if you have lung disease or experience new or worsening breathing difficulties. Patients receiving Ramucirumab should report sudden breathing problems, chest discomfort, or other concerning respiratory symptoms promptly.

Driving

Cyramza is not generally expected to directly affect driving ability. However, cancer, chemotherapy, fatigue, dizziness, or other treatment-related effects may affect your ability to drive safely. Avoid driving if you feel unwell or unable to concentrate.

Pregnancy

Ramucirumab may harm an unborn baby. Inform your doctor if you are pregnant or planning to become pregnant. Your doctor will discuss appropriate contraception and treatment precautions during and after Ramucirumab therapy.

Side Effects of Cyramza 100 mg Injection

Some patients may experience side effects during Ramucirumab treatment. Commonly reported effects include:

High blood pressure
Diarrhea
Headache
Low sodium levels
Anemia
Fatigue
Decreased appetite
Nosebleeds
Abdominal pain
Swelling
Protein in the urine
Infusion-related reactions

Your doctor may perform regular blood tests, blood pressure checks, and urine tests during treatment to monitor for complications.

Serious Bleeding

Ramucirumab can increase the risk of serious bleeding. Contact your healthcare team immediately if you notice unusual bleeding, blood in the stool or urine, vomiting blood, or bleeding that does not stop easily.

Gastrointestinal Perforation

Although uncommon, Ramucirumab can cause a hole or perforation in the stomach or intestine. Seek emergency medical attention for severe or persistent abdominal pain, fever, or other sudden abdominal symptoms.

High Blood Pressure

Ramucirumab can cause or worsen hypertension. Your doctor may monitor your blood pressure regularly and temporarily stop treatment if your blood pressure becomes severely uncontrolled.

Wound Healing

Ramucirumab can interfere with wound healing. Tell your doctor before undergoing surgery. Your healthcare team may temporarily stop treatment around major surgery according to the prescribed treatment plan.

Word of Advice

Use Cyramza 100 mg Injection (Ramucirumab) only under the supervision of your oncologist. Do not attempt to self-administer the medicine or change your treatment schedule without medical advice.

Keep the vial refrigerated at 2°C to 8°C, protect it from light, and do not freeze or shake it.

Regular monitoring is an important part of Ramucirumab treatment. Your doctor may check blood pressure, blood counts, urine protein, liver function, and other parameters during therapy.

Inform your doctor before any planned surgery and report unusual bleeding, severe abdominal pain, severe headache, vision changes, seizures, chest pain, breathing difficulty, or other serious symptoms immediately.